|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.22 USD | -0.72% |
|
-1.50% | -2.58% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Oncology and Dermatology Pharmaceutical Products | 298.63Cr | 339.46Cr | 369.56Cr | 424.12Cr | 514.12Cr | |||||
Total Assets | 493.34Cr | 584.1Cr | 678.21Cr | 544.43Cr | 695.8Cr | |||||
Interest Expense | -19.08L | -26.66L | -25.51L | -22.8L | -24.28L | |||||
Income Tax Expense | -38Cr | 19Cr | 24Cr | 28Cr | 38Cr | |||||
CAPEX | -18Cr | -7.78Cr | -3.25Cr | -8.63Cr | -5.89Cr | |||||
EBT | 57Cr | 53Cr | 83Cr | 32Cr | 166.45Cr | |||||
D&A | 6.05Cr | 6.79Cr | 8.27Cr | 8.92Cr | 9.33Cr | |||||
Operating Income | 59Cr | 58Cr | 62Cr | 6.14Cr | 151.49Cr | |||||
Net Income | 95Cr | 34Cr | 60Cr | 3.26Cr | 128.66Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 290Cr | 320Cr | 350Cr | 400Cr | 479.99Cr | |||||
Total Assets | 43Cr | 44Cr | 43Cr | 47Cr | 41Cr | |||||
Europe | 12Cr | 15Cr | - | 26Cr | 32Cr | |||||
Total Assets | 29Cr | 30Cr | 31Cr | - | - | |||||
Total Assets | 29L | 15L | 48L | - | - | |||||
Other Countries | - | - | - | 62L | 1.76Cr | |||||
Total Assets | - | - | - | 1.17Cr | 1.43Cr | |||||
Europe and Japan | - | - | 18Cr | - | - | |||||
Total Assets | - | - | - | 28Cr | 31Cr |
- Stock Market
- Equities
- INCY Stock
- Financials Incyte Corporation
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition